309 related articles for article (PubMed ID: 28031527)
1. Tumor-initiating cells of breast and prostate origin show alterations in the expression of genes related to iron metabolism.
Rychtarcikova Z; Lettlova S; Tomkova V; Korenkova V; Langerova L; Simonova E; Zjablovskaja P; Alberich-Jorda M; Neuzil J; Truksa J
Oncotarget; 2017 Jan; 8(4):6376-6398. PubMed ID: 28031527
[TBL] [Abstract][Full Text] [Related]
2. Mitochondrially targeted vitamin E succinate efficiently kills breast tumour-initiating cells in a complex II-dependent manner.
Yan B; Stantic M; Zobalova R; Bezawork-Geleta A; Stapelberg M; Stursa J; Prokopova K; Dong L; Neuzil J
BMC Cancer; 2015 May; 15():401. PubMed ID: 25967547
[TBL] [Abstract][Full Text] [Related]
3. Integrative analyses of gene expression and DNA methylation profiles in breast cancer cell line models of tamoxifen-resistance indicate a potential role of cells with stem-like properties.
Lin X; Li J; Yin G; Zhao Q; Elias D; Lykkesfeldt AE; Stenvang J; Brünner N; Wang J; Yang H; Bolund L; Ditzel HJ
Breast Cancer Res; 2013 Dec; 15(6):R119. PubMed ID: 24355041
[TBL] [Abstract][Full Text] [Related]
4. AhR ligand aminoflavone suppresses α6-integrin-Src-Akt signaling to attenuate tamoxifen resistance in breast cancer cells.
Campbell PS; Mavingire N; Khan S; Rowland LK; Wooten JV; Opoku-Agyeman A; Guevara A; Soto U; Cavalli F; Loaiza-Pérez AI; Nagaraj G; Denham LJ; Adeoye O; Jenkins BD; Davis MB; Schiff R; Brantley EJ
J Cell Physiol; 2018 Jan; 234(1):108-121. PubMed ID: 30076704
[TBL] [Abstract][Full Text] [Related]
5. AhR ligand Aminoflavone inhibits α6-integrin expression and breast cancer sphere-initiating capacity.
Brantley E; Callero MA; Berardi DE; Campbell P; Rowland L; Zylstra D; Amis L; Yee M; Simian M; Todaro L; Loaiza-Perez AI; Soto U
Cancer Lett; 2016 Jun; 376(1):53-61. PubMed ID: 26996297
[TBL] [Abstract][Full Text] [Related]
6. mTOR inhibitors counteract tamoxifen-induced activation of breast cancer stem cells.
Karthik GM; Ma R; Lövrot J; Kis LL; Lindh C; Blomquist L; Fredriksson I; Bergh J; Hartman J
Cancer Lett; 2015 Oct; 367(1):76-87. PubMed ID: 26208432
[TBL] [Abstract][Full Text] [Related]
7. First-in-class candidate therapeutics that target mitochondria and effectively prevent cancer cell metastasis: mitoriboscins and TPP compounds.
Ózsvári B; Sotgia F; Lisanti MP
Aging (Albany NY); 2020 May; 12(11):10162-10179. PubMed ID: 32452826
[TBL] [Abstract][Full Text] [Related]
8. HOXB5 Confers Tamoxifen Resistance in Breast Cancer Cells and Promotes Tumor Aggression and Progression.
Kim CY; Kim YC; Oh JH; Kim MH
Anticancer Res; 2021 Jul; 41(7):3409-3417. PubMed ID: 34230136
[TBL] [Abstract][Full Text] [Related]
9. Nicastrin and Notch4 drive endocrine therapy resistance and epithelial to mesenchymal transition in MCF7 breast cancer cells.
Lombardo Y; Faronato M; Filipovic A; Vircillo V; Magnani L; Coombes RC
Breast Cancer Res; 2014 Jun; 16(3):R62. PubMed ID: 24919951
[TBL] [Abstract][Full Text] [Related]
10. The effects of telomerase inhibition on prostate tumor-initiating cells.
Marian CO; Wright WE; Shay JW
Int J Cancer; 2010 Jul; 127(2):321-31. PubMed ID: 19908230
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of STAT3 signaling targets both tumor-initiating and differentiated cell populations in prostate cancer.
Han Z; Wang X; Ma L; Chen L; Xiao M; Huang L; Cao Y; Bai J; Ma D; Zhou J; Hong Z
Oncotarget; 2014 Sep; 5(18):8416-28. PubMed ID: 25261365
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan.
Hiscox S; Baruha B; Smith C; Bellerby R; Goddard L; Jordan N; Poghosyan Z; Nicholson RI; Barrett-Lee P; Gee J
BMC Cancer; 2012 Oct; 12():458. PubMed ID: 23039365
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer patient-derived scaffolds as a tool to monitor chemotherapy responses in human tumor microenvironments.
Leiva MC; Garre E; Gustafsson A; Svanström A; Bogestål Y; Håkansson J; Ståhlberg A; Landberg G
J Cell Physiol; 2021 Jun; 236(6):4709-4724. PubMed ID: 33368325
[TBL] [Abstract][Full Text] [Related]
14. High expression of TROP2 characterizes different cell subpopulations in androgen-sensitive and androgen-independent prostate cancer cells.
Xie J; Mølck C; Paquet-Fifield S; Butler L; ; Sloan E; Ventura S; Hollande F
Oncotarget; 2016 Jul; 7(28):44492-44504. PubMed ID: 27283984
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA expression analysis of mammospheres cultured from human breast cancers.
Feifei N; Mingzhi Z; Yanyun Z; Huanle Z; Fang R; Mingzhu H; Mingzhi C; Yafei S; Fengchun Z
J Cancer Res Clin Oncol; 2012 Nov; 138(11):1937-44. PubMed ID: 22752669
[TBL] [Abstract][Full Text] [Related]
16. Selective AKT Inhibition by MK-2206 Represses Colorectal Cancer-Initiating Stem Cells.
Malkomes P; Lunger I; Luetticke A; Oppermann E; Haetscher N; Serve H; Holzer K; Bechstein WO; Rieger MA
Ann Surg Oncol; 2016 Sep; 23(9):2849-57. PubMed ID: 27059026
[TBL] [Abstract][Full Text] [Related]
17. High mitochondrial mass identifies a sub-population of stem-like cancer cells that are chemo-resistant.
Farnie G; Sotgia F; Lisanti MP
Oncotarget; 2015 Oct; 6(31):30472-86. PubMed ID: 26421710
[TBL] [Abstract][Full Text] [Related]
18. Indoleamine-2,3-dioxygenase elevated in tumor-initiating cells is suppressed by mitocans.
Stapelberg M; Zobalova R; Nguyen MN; Walker T; Stantic M; Goodwin J; Pasdar EA; Thai T; Prokopova K; Yan B; Hall S; de Pennington N; Thomas SR; Grant G; Stursa J; Bajzikova M; Meedeniya AC; Truksa J; Ralph SJ; Ansorge O; Dong LF; Neuzil J
Free Radic Biol Med; 2014 Feb; 67():41-50. PubMed ID: 24145120
[TBL] [Abstract][Full Text] [Related]
19. lncMat2B regulated by severe hypoxia induces cisplatin resistance by increasing DNA damage repair and tumor-initiating population in breast cancer cells.
García-Venzor A; Mandujano-Tinoco EA; Ruiz-Silvestre A; Sánchez JM; Lizarraga F; Zampedri C; Melendez-Zajgla J; Maldonado V
Carcinogenesis; 2020 Nov; 41(11):1485-1497. PubMed ID: 32710610
[TBL] [Abstract][Full Text] [Related]
20. Inhibiting PAD2 enhances the anti-tumor effect of docetaxel in tamoxifen-resistant breast cancer cells.
Li F; Miao L; Xue T; Qin H; Mondal S; Thompson PR; Coonrod SA; Liu X; Zhang X
J Exp Clin Cancer Res; 2019 Oct; 38(1):414. PubMed ID: 31601253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
